Stockreport

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease [Yahoo! F...

Fortress Biotech, Inc.  (FBIO) 
Last fortress biotech, inc. earnings: 11/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: fortressbiotech.com
PDF CUTX-101 has potential to be the first FDA-approved treatment for Menkes disease, a rare and fatal pediatric disease SOLANA BEACH, Calif. and AHMEDABAD, India and MIA [Read more]